View Item 

Show simple item record

Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents
dc.contributor.authorChan, Francis K. L.en_US
dc.contributor.authorAbraham, Neena S.en_US
dc.contributor.authorScheiman, James M.en_US
dc.contributor.authorLaine, Lorenen_US
dc.date.accessioned2010-06-01T19:01:44Z
dc.date.available2010-06-01T19:01:44Z
dc.date.issued2008-11en_US
dc.identifier.citationChan, Francis K.L.; Abraham, Neena S.; Scheiman, James M.; Laine, Loren (2008). "Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents." The American Journal of Gastroenterology 103(11): 2908-2918. <http://hdl.handle.net/2027.42/72218>en_US
dc.identifier.issn0002-9270en_US
dc.identifier.issn1572-0241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72218
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18853980&dopt=citationen_US
dc.format.extent206365 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2008 American College of Gastroenterology/Blackwell Publishingen_US
dc.titleManagement of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agentsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan Medical School, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDepartment of Medicine & Therapeutics, Chinese University of Hong Kong, Hong Kongen_US
dc.contributor.affiliationotherHouston Center of Quality of Care and Utilization Studies, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; Sections of Gastroenterology and Health Services Research Department of Medicine, Baylor College of Medicine, Houston, Texasen_US
dc.contributor.affiliationotherKeck School of Medicine, University of Southern California, Los Angeles, Californiaen_US
dc.identifier.pmid18853980en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72218/1/j.1572-0241.2008.02200.x.pdf
dc.identifier.doi10.1111/j.1572-0241.2008.02200.xen_US
dc.identifier.sourceThe American Journal of Gastroenterologyen_US
dc.identifier.citedreferenceBidaut-Russell M, Gabriel SE. Adverse gastrointestinal effects of NSAIDs: Consequences and costs. Best Pract Res Clin Gastroenterol 2001; 15: 739 – 53.en_US
dc.identifier.citedreferenceVonkeman HE, Klok RM, Postma MJ, et al.. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs. Drugs Aging 2007; 24: 681 – 90.en_US
dc.identifier.citedreferenceBresalier RS, Sandler RS, Quan H, et al.. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl Med 2005; 352: 1092 – 102.en_US
dc.identifier.citedreferenceSolomon SD, McMurray JJV, Pfeffer MA, et al.. For the Adenoma Prevention with Celecoxib (APC) Study Investigators Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. N Engl Med 2005; 352: 1071 – 80.en_US
dc.identifier.citedreferenceNussmeier NA, Whelton AA, Brown MT, et al.. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081 – 91.en_US
dc.identifier.citedreferenceKearney PM, Baigent C, Godwin J, et al.. Do selective cyclo-oxygenase-2 inhibitors and nonselective non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302 – 8.en_US
dc.identifier.citedreferenceMcGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633 – 44.en_US
dc.identifier.citedreferenceAbraham NS, El-Serag HB, Hartman C, et al.. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007; 25: 913 – 24.en_US
dc.identifier.citedreferenceJuni P, Nartey L, Reichenbach S, et al.. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004; 364: 2021 – 9.en_US
dc.identifier.citedreference10.  US Food and Drug Administration: Drug Information. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Available at: http://www.fda.gov/cder/drug/infopage/cox2/default.htm. Accessed August 8, 2006.en_US
dc.identifier.citedreferenceSchnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol 2006; 25 ( Suppl 1 ): S22 – 9.en_US
dc.identifier.citedreferenceTannenbaum H, Bombardier C, Davis P, et al.. ( Third Canadian Consensus Conference Group ). An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006; 33: 140 – 57.en_US
dc.identifier.citedreferenceAmerican Gastroenterological Association, Wilcox CM, Allison J, Benzuly K, et al.. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006; 4: 1082 – 9.en_US
dc.identifier.citedreferenceAntman EM, Bennett JS, Daugherty A, et al.; American Heart Association. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation 2007; 115: 1634 – 42.en_US
dc.identifier.citedreferenceDubois RW, Melmed GY, Henning JM, et al.. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004; 19: 197 – 208.en_US
dc.identifier.citedreferenceHallas J, Lauritsen J, Villadsen HD, et al.. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol. 1995; 30: 438 – 44.en_US
dc.identifier.citedreferenceHippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 2005; 331: 1310 – 6.en_US
dc.identifier.citedreferenceGarcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769 – 72.en_US
dc.identifier.citedreferenceLaine L, Bombardier C, Hawkey CJ, et al.. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123: 1006 – 12.en_US
dc.identifier.citedreferenceGabriel SE, Jaakkimainen L, Bombardier C. Risks for serious gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs: A meta-analysis. Ann Intern Med 1991; 115: 787 – 96.en_US
dc.identifier.citedreferencePiper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735 – 40.en_US
dc.identifier.citedreferenceLanas A, GarcÍa-RodrÍguez LA, Arroyo MT, et al.; AsociaciÓn EspaÑola deGastroenterologÍa. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731 – 8.en_US
dc.identifier.citedreferenceGarcÍa RodrÍguez LA, RuigÓmez A. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology 1999; 10: 228 – 32.en_US
dc.identifier.citedreferencePatrono C, GarcÍa RodrÍguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373 – 83.en_US
dc.identifier.citedreference25.  National Cholesterol Education Program: Third report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Risk assessment tool for estimating 10-year risk of developing hard CHD (myocardial infarction and coronary death). Available at: http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof. Accessed August 8, 2006.en_US
dc.identifier.citedreferenceHooper L, Brown TJ, Elliott R, et al.. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: Systematic review. BMJ 2004; 329: 948.en_US
dc.identifier.citedreferenceMoore RA, Derry S, Phillips CJ, et al.. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: Review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006; 7: 79.en_US
dc.identifier.citedreferenceRostom A, Muir K, Dube C, et al.. Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818 – 28.en_US
dc.identifier.citedreferenceRostom A, Dube C, Wells G, et al.. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002 ;( 4 ): CD002296.en_US
dc.identifier.citedreferenceHawkey CJ, Karrasch JA, Szezepanski L, et al: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727 – 34.en_US
dc.identifier.citedreferenceGraham DY, Agrawal NM, Campbell DR, et al.. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162: 169 – 75.en_US
dc.identifier.citedreferenceSilverstein FE, Graham DY, Senior JR, et al.. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241 – 9.en_US
dc.identifier.citedreferenceChan FK, Chung SC, Suen BY, et al.. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967 – 73.en_US
dc.identifier.citedreferenceChan FK, Wong VW, Suen BY, et al.. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomised trial. Lancet 2007; 369: 1621 – 6.en_US
dc.identifier.citedreferenceLanas A, Bajador E, Serrano P, et al.. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834 – 9.en_US
dc.identifier.citedreferenceLaine L, Curtis SP, Cryer B, et al. MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomized comparison. Lancet 2007; 369: 465 – 73.en_US
dc.identifier.citedreferenceHasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000; 32: 1008 – 15.en_US
dc.identifier.citedreferenceFink A, Kosecoff J, Chassin M, et al.. Consensus methods: Characteristics and guidelines for use. Am J Public Health 1984; 74: 979 – 83.en_US
dc.identifier.citedreferenceGordon TJ. The Dephi method. In: Glenn JC, Gordon TJ, eds. AC/UNU millennium project: Futures research methodology, version 2.0. Washington, DC: United Nations University, 2003: 1 – 30.en_US
dc.identifier.citedreferenceKeeney S, Hasson F, McKenna H. Consulting the oracle: Ten lessons from using the Delphi technique in nursing research. J Adv Nurs 2006; 53: 205 – 12.en_US
dc.identifier.citedreferenceChan FK, Hung LC, Suen BY, et al.. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104 – 10.en_US
dc.identifier.citedreferenceChan FK, Hung LC, Suen BY, et al.. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial. Gastroenterology 2004; 127: 1038 – 43.en_US
dc.identifier.citedreferenceLai KC, Chu KM, Hui WM, et al.. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118: 1271 – 8.en_US
dc.identifier.citedreferenceScheiman JM, Yeomans ND, Talley NJ, et al.. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701 – 10.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1572-0241.2008.02200.x.pdf
Size:
201.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.